Family Holding Company
Principal capital for inventions that change medicine.
Each Focus is a privately held family company. We back disruptive biotech inventions before institutional capital is interested. No fund timelines. No exits on the calendar. We hold what we build.
We back the inventions that change how medicine works.
Medicine advances in two ways. Incremental improvements to existing treatments, and inventions that reset the floor of what is possible. We hold the second kind.
The inventions we back share a pattern. They emerge from working scientists and clinical operators rather than corporate research budgets. They sit at the edge of an FDA pathway that does not exist yet, or one that is too narrow to fit them. They have a clinical signal that does not need polishing. And they have founders who plan to be in the room when the first patient is treated.
We are not a fund. We do not raise from outside investors. The capital is family. The horizon is generational. The accountability is to patients and to the next family member who inherits the position.
Four categories where we hold positions.
Mesenchymal Exosome Biologics
Cell-derived therapeutics on the 351(a) Biologics License pathway. Inflammation, damaged tissue, immunomodulation. Manufacturing under cGMP, clinical development under IND.
Targeted Oncology Lysis
A platform that lyses tumor cells through targeted osmotic disruption. Non-toxic to surrounding tissue. Translational work in solid tumor cancers underway with academic medical center collaborators.
Regenerative Spinal Medicine
FDA-cleared procedural innovations for degenerative disc disease and chronic back pain. Clinical operators using next-generation imaging, ablation, and biologic adjuncts.
Frontier Therapeutics
HCT/P translation, cellular oncology, and category-defining diagnostics that sit outside conventional venture timelines. We expect long arcs and stay through them.
How we hold what we hold.
Primary capital, not pass-through
Every dollar we deploy is family principal. No LP timelines, no fund return models, no pressure to exit before a clinical milestone is reached.
Founder operators, not consultant builders
We back inventions whose founders intend to operate them through clinical translation. We hold positions where the scientist or clinician is still in the room.
Regulatory rigor as a feature
We pick pathways that the FDA can read. 351(a) BLA when warranted. 510(k) and De Novo where they fit. RMAT designation pursued when the data supports it. No regulatory arbitrage.
Patients first, exits last
Our held positions measure success in patients treated, not in markup events. Liquidity arrives when the science is finished, not when the cap table is convenient.
Frequently asked.
Are you a venture fund?
No. Each Focus is a family holding company. We do not raise from outside investors. We do not accept LP capital. Our positions are held with principal capital on generational horizons.
Do you take inbound pitches?
Selectively. Inbound is reviewed when an introduction comes from a working clinical operator, an academic medical center principal investigator, or a regulatory counsel we already work with.
What stage do you back?
Pre-IND through Phase 2 for biologics. Pre-510(k) through post-clearance for devices. Pre-clinical translation work for HCT/P and cellular therapeutics. We are stage-agnostic when the invention is right.
Where are you based?
Dallas, Texas. Our portfolio operators are across the United States and Europe.
Are you regulated?
As a single family office investing only its own principal, Each Focus is not a registered investment adviser and does not solicit, accept, or manage outside capital.
If your invention belongs here, write us.
Introductions from working clinicians, scientists, and regulatory counsel are read first. relations@eachfocus.org